Evofem Biosciences, Inc. Common Stock
EVFM
EVFM was delisted on the 10th of August, 2022.
68 hedge funds and large institutions have $9.84M invested in Evofem Biosciences, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 14 increasing their positions, 17 reducing their positions, and 5 closing their positions.
399% more call options, than puts
Call options by funds: $714K | Put options by funds: $143K
120% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 5
11% more capital invested
Capital invested by funds: $8.84M → $9.84M (+$1M)
10% more funds holding
Funds holding: 62 → 68 (+6)
18% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MCP
Mirador Capital Partners
Pleasanton,
California
|
+$1.14M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$118K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$66.8K |
| 4 |
Morgan Stanley
New York
|
+$38K |
| 5 |
TAM
Tocqueville Asset Management
New York
|
+$21.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$1.01M |
| 2 |
D.E. Shaw & Co
New York
|
-$741K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$347K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$197K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$185K |
EVFM Hedge Fund Activity: Q1 2022 in Review
68 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Evofem Biosciences, Inc. Common Stock (EVFM) for Q1 2022, worth a combined $9.84M — up 11% from $8.84M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new EVFM positions and 5 closed out — a net gain of 6 holders — while 14 added to existing stakes and 17 trimmed.
The largest buyer was Mirador Capital Partners, adding an estimated $1.14M. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $1.01M sold.
- 68 institutional investors held Evofem Biosciences, Inc. Common Stock (EVFM) as of Q1 2022, up from 62 in Q4 2021.
- Funds reported $9.84M of Evofem Biosciences, Inc. Common Stock stock for Q1 2022, up 11% quarter-over-quarter.
- 11 funds opened new Evofem Biosciences, Inc. Common Stock positions in Q1 2022 and 5 closed out, a net change of +6 holders.
- The largest Evofem Biosciences, Inc. Common Stock buyer in Q1 2022 was Mirador Capital Partners, an estimated $1.14M added.
- The largest Evofem Biosciences, Inc. Common Stock seller in Q1 2022 was Baker Bros. Advisors, an estimated $1.01M sold.
Based on aggregated 13F filings for Q1 2022.